Navigation Links
Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Date:6/24/2011

>

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideli
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
(Date:7/25/2014)... BENSALEM, Pa. , July 25, 2014 /PRNewswire-iReach/ ... services and consulting for global corporations operating in ... will host its first annual Global User Group ... in historic Philadelphia, Pennsylvania ... Photo - http://photos.prnewswire.com/prnh/20140724/130263 ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... , , Mark Churchill and Mark Harrison, Thermo Finnigan, , ... , , Bioanalytical Method Validation , ... using , a Thermo Finnigan TSQ Quantum mass spectrometer, , ... , , , , Guidelines on Bioanalytical ...
... , , , , , , ... Beecham Pharmaceuticals , , Metabolite ... Finnigan LCQ , Series of ion trap mass spectrometers. , ... , An integral part of the process by ...
... , , , , Jack Cunniff, Philip Tiller, Michael Harvey, ... , , , , , ... using the Thermo Finnigan LCQ , Series of ion trap mass spectrometers. , ... , For more than five thousand years tea has been used in ...
Cached Biology Technology:Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 2Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 3Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 4Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 5Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 6In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 2In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 3In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 4In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 5In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 6Structural Determination of Flavonoids Using MSn 2Structural Determination of Flavonoids Using MSn 3Structural Determination of Flavonoids Using MSn 4
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... what they want, to paraphrase the Rolling Stones, but sometimes ... that will appear in the May issue of the ... broad sweep of evolutionary changes in life on earth as ... shifts. And yet the amount of variability seen among successive ...
... ,PORTLAND, Ore. April 2, 2010. Countless studies and reports exist ... is the impact on the soil? Should one leave the ... offsite in preparation for replanting the area in the future? ... possible, that the debris remaining on the ground after logging ...
... (ACMGF) has awarded Dr. Marilyn M. Li, of the ... Medicine the 2010-2011 Luminex/ACMGF Award at the ACMG 2010 ... includes a $100,000 grant and is aimed at the ... including the development of research guidelines. "Medical ...
Cached Biology News:Ecologists receive mixed news from fossil record 2Study reveals that logging debris suppresses development of an invasive competitor, Scotch broom 2Dr. Marilyn M. Li, M.D., FACMG, is the 2010 Luminex/ACMGF award recipient 2
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Antibeta-lactoglobulin monoclonal antibody(CD-2)...
MAb to Vasopressin Preservative: NaN3...
Biology Products: